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Human platelets, prelabeled with PzP]phospate were treated with tctradecanoylphorbol acetate (TPA) for 5 min at 37°C. Phosphorylation of the 
components of adenylyl cyclase was determined in membranes using specific antibodies against G-proteins and the catalytic moiety. Less than 0.01 
mol of PaP]phosphate/mol could be detected in immunoprecipitates using antibodies against sequences within the or-subunit of the GPP binding 
protein Gi. TPA, however, caused the incorporation of 0.67-1.1 mol of P”P]phosphate per mol of catalyst while 0.13X1.2 mol were found in the 
absence of TPA. Lack of modification of the or-subunit of Gi was also indicated by the results of reconstitution experiments with purified Gi, from 
bovine brain: adenylyl cyclase in membranes from untreated platelets was significantly more inhibited by added Gi,, than that from TPA treated 
cells. While P,y-subunits were like-wise inhibitory no difference dependent on platelet-pretreatment could be observed. 
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1. INTRODUCTION 
Hormonal inhibition of adenylyl cyclase is mediated 
by a coupling component, termed Gi, which belongs to 
the family of GTP-binding proteins exhibiting c~,P,y- 
configuration [l]. At the moment three different ai- 
subunits are known (ail, ai2, ai3) whish, because they 
can serve as substrates for pertussis toxin, may also be 
implicated in the regulation of phospholipase C activity 
[ 1,2]. The identity of the ai moiety involved in these two 
pathways remains to be established, although a recent 
report does present evidence for ai being invo!ved in 
inhibition of adenylyi cyclase [3]. The mechanism of 
hormonal inhibition is also still a matter of debate, 
since direct effects (interactions of ai and/or /3,-y- 
complex with the catalyst) and indirect effects (in- 
terference by &y-complex with the activation of G,) 
hsve been discussed [4,5]. 
There is also functional evidence for cross-talk bet- 
Abbreviuriom TPA, tetradecanoylphorbol acetate: Gpp(NH)p, 
guanosine 5 ‘-(&y-imido)triphosphate; GTPrS, guanosine 5’-(y- 
thio)-triphosphate; C, catalytic component of adenylyl cyclase; Gr, 
guanine nucleotide binding regulatory component responsible for 
stimulation of adenylyl cyclase; Gi. guanine nucleotide binding 
regulatory component responsible for inhibition of adenylyl cyclase, 
SDS; sodium dodecyl sulfate. 
E~?zyrrres: adenylyl cyclase (EC 4.G.l.l), alkaline phosphatase (EC 
3.1.3.1), creatine kinase (EC 2.7.3.2). 
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ween the adenylyl cyclase and the phospholipase C 
signalling pathways at the level of Gi. Therefore in- 
volvement of protein kinase C as a modulator seems to 
be possible. Attenuation of hormonal inhibition of 
diacylglycerol and phorbol esters has been recently 
demonstrated in human platelets [6,‘7]. In fact, 
r.hosphorylation of Gi, seemed to be a particularly at- 
tractive postulate, since it has been demonstrated that 
purified Gi from liver could be readily phosphorylated 
in vitro with an acceptable stoichiometry of 0.5 mol 
[32P]pllosphate incorporated per mol of Gi, [8]. 
Several groups have tried to demonstrate hormonally 
induced or phorbol ester-induced phosphorylation of 
platelet Cii, in vivo. Crouch and Lapetina 191 showed 
[32P]phosphate-labeling of a 41 kDa protein after im- 
munoprecipitation, but no stoichiometry was reported. 
However, a recent investigation by Carlson et al. [lo] 
did not reveal [32P]phosphorylation of Gi, after 
stimulation with TPA analysed by antibodies against 
two different sequences of Gi,. Instead, [32P]phosphate 
incorporation into a 40 kDa protein was demonstrated 
which was immunoprecipitated with antibodies design- 
ed for specific detection of a novel G, species termed (_yZ 
[ 11,121. The functional importance of this 40 kDa pro- 
tein is unknown. It is not a likely target for attenuation 
of hormonal inhibition because it lacks the consensus 
sequence for ADP-ribosykation by pertussis toxin and 
the hormonal inhibition of adenylyl cyclase is readily 
neutralized by that toxin [13]. Recently, evidence was 
presented that ai2 was phosphorylated in hepatocytes 
treated with TPA (and certain hormones) concomitant 
with loss of Gpp(NH)p-inhibitable adenylyl cyclase ac- 
tivity [14,15]. 
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It was the aim of this paper therefore to re-examine 
a possible phosphorylation of coupling proteins but 
also to extend investigations to the catalytic subunit of 
the adenylyl cyclase system. Furthermore, the func- 
tional interactions of purified subunits of Gi following 
reconstitution with the phorbol ester modified adenylyl 
cyclase system of platelets were analysed. 
2. MATERIALS AND METHODS 
2.1. Materials 
Tetradecanoylphorbol acetate (TPA), apyrase, PGEt, epinephrine, 
pertussis toxin, cholera toxin, benzethonium chloride and ben- 
zamidine were purchased from Sigma (Munich). Gpp(NH)p. GTPyS, 
creatine phosphate, creatine kinase were obtained from Boehringer, 
Mannheim. Pansorbin (Slu~hy/ococcus arrrerts cells) was from 
Calbiochem and Trasylol from Bayer. All other chemicals were of the 
highest purity available. 
Radiochemicals: Na[‘Z51], carrier-free, [~x-~*P]ATP (760 CVmmol, 
I mCi = 37 MB@. [“P]orthophosphate carrier-free, [‘HIcAMP 
(15-30 Ci/mmol) were obtained from Amersham Buchler, 
Braunschweig. 
Buffers: RIPA [16]: 150 mM NaCl, IOmM sodium phosphate, 1% 
sodium deoxycholate. 0.5% SDS, 1% Nonidet P 40, 1 mM DTE, pH 
7.4. Physiological HEPES buffer: 20 mM HEPES, 140 mM NaCl, 2.9 
mM KCI, 1 mM MgCIz, I mM EGTA, I mM glucose, pH 7.4. 
2.2. Treatment of platelets lvith phor&ol esters 
This was performed essentially according to the method of 
Williams et al. [S]. Platelet-rich plasma (4- to 5-days-old) obtained 
from the DRK Wilrzburg). was centrifuged for 10 min at 160 x g in 
order to remove any residual erythrocytes. The supernatant was cen- 
trifuged at 22°C at 1000 x g for 15 min and the cell pellet washed for 
15 min at 1000 x g twice with physiological HEPES buffer (22°C). 
Platelets were adjusted to - IO9 cells/ml in tbe same buffer and in- 
cubated for 20 min at 37°C which 0.6 U/ml apyrase and 1 mM 
aspirin. The cells were centrifuged at 22°C (1000 x g. 15 min) and 
resuspended at the same density in the above buffer (37°C) containing 
only apyrase. 
Following addition of [‘“Plorthophosphate (500 &i/ml) and in- 
cubation for 90 min at 37°C. 2 mM creatine phosphate and 0.8 mg/ml 
creatine kinase were added and the mixture incubated for further 5 
min. followed by stimulation with TPA (1 aM) for 5 min at 37°C. The 
action of TPA was stopped by the addition of the same volume of ice- 
cold buffer and centrifugation at I200 x g for 5 min (4°C). When 
cells were not prelabeled with [3LP]phosphate, TPA was added direct- 
ly following a 5 min prewarming period. The pellet was resuspended 
in 20 vols. of 10 mM sodium pyrophosphate, 10 mM NaF. 5 mM ED- 
TA, 1 me/ml Trasylol, 1 mM benzamidine, 0.1 mM benzethonium 
chloride, 0.1 mM sodium metavanadate, 40 PM phenylmethyl- 
sulphonyl fluoride pH 7.4. Lysis was induced by repeated freeze- 
thawing (liquid nitrogen/waterbath at 30°C). Membranes were 
washed twice with ice-cold 10 mM triethanolamine. 5 mM EDTA buf- 
fer pH 7.4 (30 000 x g, I5 min) and resuspended in the same buf- 
fer/10% glycerol at a protein concentration of 5-10 mg/ml. Mem- 
branes were stored at - 70°C. 
2.3. Preparation of antibodies and irnrnunoprecipitation 
(a) Antibodies against the adenylyl cyclase catalyst. Preparation of 
ascites fluid containing monoclonal antibody BBC-4 and its isolation 
from ascites have been described previously [l7]. A covalent 
Pansorbin-anti-adenylyl cyclase conjugate was prepared according to 
Schneider et al. [lg]. 
(b) Antisera against peptide sequences of G%,, 46-61 (common to 
all (Y subunits except rrl, serum 6702) and 379-394 (specific for ols, 
serum 6712) were obtained after coupling of peptides to serum 
albumin followed by immunization of New Zealand White rabbits 
WI. 
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The efficiency of immunoprecipitation of the catalyst by antibody 
BBC-4 was determined by quantitative Western blot analysis of SDS- 
solubilized membranes and immunoprecipitates. Precipitation of (Ye 
and ai by antisera 6712 and 6702 was quantified using membranes 
[JLP]ADP-ribosylated with cholera toxin or pertussis toxin. Precipita- 
tion of antigens was performed as described in the legends to Figs. 1 
and 2. Precipitation efficiencies for catalyst (C), (Ye and ai were 85070, 
80% and 48%, respectively. The concentrations of C, (Ye and (Yi in 
membranes were determined by quantitative Western blot analysis us- 
ing the above mentioned antibodies and pure complex consisting of 
the catalyst and the G.,-subunit (rabbit myocardium for C, [21]), 
pure G, (turkey erythrocytes) and pure ai (bovine brain) as reference 
preparations. Eight pmol or, 30 pmol ni and 1.7 pmol C per mg of 
platelet membrane protein were found. 
2.4. SDS-polyacrylamide gel electrophoresis and Western blot 
analysis 
For analysis of cr-subunits of G-protein, 1 I% polyacrylamide gels 
and for analysis of the catalytic subunit of adenylyl cyclase 5-15% 
gradient gels were used. Transfer of the catalyst to nitrocellulose was 
in the presence of 0.025% SDS. Antigens for antisera 6702 (Q) and 
6712 (cx,) were visualized with radio-iodinated protein A, while the 
catalyst (C) was stained directly with radioiodinated monoclonal an- 
tibody BBC-4 [17]. For autoradiography. gelsand Western blots were 
exposed to Kodak XAR 5 films using intensifying screens (Siemens 
Titan 2 HS). Molecular mass standards (kDa) were myosin (200). /3- 
galactosidase (116). phosphorylase b (97), bovine serum albumin (68). 
ovalbumin (45) and carbonic anhydrase (3q). 
2.5. Detemination of the stoichiometry of phosplrorytation of 
ndenylyl cycluse components 
The specific radioactivity of [(u-“P]ATP in platelet lysates was 
determined according to (221 exploiting the stoichiometric (1:l) 
autophosphorylation of the regulatory subunit of CAMP-dependent 
protein kinase from bovine heart. A considerable fraction of the ATP 
resides in dense granules inside the platelet that is not metabolically 
labeled and does not participate in cytosolic phosphorylation reac- 
tions 1231. Since this ATP pool adds to the cytosolic [“P]ATP after 
quenching with perchloric acid [22], a correction of the specific 
radioactivity had to be made according to the data of Meyers et al. 
[23]. Therefore the value for the specific radioactivity of ATP was 
multiplied by a factor of 1.54. 
The amount of [“Pjphosphate incorporated into components of 
the adenylyl cyclase complex was computed as follows: 
Incorporation (mol/mol) = 
A 
D x c x 1.54 
A = [32P] radioactivity in relevant area on polyacrylamide gel (cpm) 
B = amount of adenylyl cyclase component applied to gel (pmol) 
C = specific radioactivity of ATP pool (cpm x pmol- ‘) 
2.6. Miscellaneous procedures 
Preparation of G, from turkey erythrocytes was performed accor- 
ding to [24]. ai, (Y~ and fl,y-complex were isolated from bovine brain 
following published procedures [25-271 with minor modifications. 
The subspecies composition of ai (83% (nil and 17% cr,~) was deter- 
mined after [32P]ADP-ribosylation and separation by polyacrylamide 
gel electrophoresis in the presence of SDS/urea according to [ZS]. 
Adenylyl cyclase activity was measured in 30 mM MOPS, pH 7.4, 
15 mM crcatine phosphate, 50 wg/ml creatine kinase, 4.5 mM 
theophylline, 2 mM MgClz, 1 mM dithioerythritol, 2 mg/ml bovine 
serum albumin, 0.1 mM [“P]ATP (l-2 x 10” cpm/test tube) for 20 
min at 30°C. 
Labeling of membrane bound err and ai by [“PJADP-ribosylation 
via cholera toxin or pertussis toxin was performed according to 
published procedures [29,30]. 
Protein estimation was performed according to Lowry et al. [3l] or 
according to Schultz et al. [32]. Protein A, molecular mass standards 
and anti-adenylyl cyclase antibody BBC-4 were radio-iodinated accor- 
ding to Greenwood et al. [33]. 
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3. RESULTS AND DISCUSSION 
Short-term treatment of human platelets with TPA 
leads to attenuation of epinephrine inhibition of several 
functions of adenylyl cyclase such as stimulation by 
PGEt and forskolin. We can confirm the observations 
of Johnson et al. [34] with S49 cells that inhibition by 
GTP-analogs like Gpp(NW)p was also impaired follow- 
ing treatment with phorbolesters. A second conse- 
quence of such treatment was enhancement by 
30-100% of the enzymatic activity induced by various 
stimuli, among them exogenous activated G,, purified 
from turkey erythrocytes. It should be noted that the 
amount of G, to reach half-maximal stimulation was 
the same before and after TPA treatment. Typical 
results demonstrating the influence of TPA on stimula- 
tion and inhibition of adenylyl cyclase may be seen in 
Fig. 3. 
To examine phosphorylation of the components of 
the adenylyl cyclase systems we labeled the ATP-pool 
of intact human platelets with [32P]orthophosphate for 
90 min followed by brief treatment with 1 PM TPA. For 
analysis of Gs,- and Gi,-modification, antibodies 
against the C-terminal hexadecapeptide of G,, and 
against a sequence (46-61) common to a-subunits of 
G,, Gi, G, (but not G,) was used. This type of antibody 
also precipitates Gi,-subtypes to a similar extent [3S]. A 
recently described monoclonal antibody, BBC-4, raised 
against adenylyl cyclase from bovine brain was ex- 
ploited to monitor the catalytic unit [36]. This antibody 
was shown to recognize an epitope common to adenylyl 
cyclases from a variety of tissues and species [21,37]. 
More recent data have revealed that this antibody binds 
to a portion of a 21 amino-acid synthetic peptide iden- 
tical with sequences within the catalyst from bovine 
brain (Cat ’ -sensitive) and rabbit myocard (Ca2 + -in- 
sensitive) with the exception of one conservative 
replacement (Arg-rLys) (J. Wallach and S. Mollner, 
unpublished). 
Fig. 1 shows the autoradiographs of SDS gels obtain- 
ed after immunoprecipitation with anti-G, antibodies 
of [32P]phosphate-labeled platelets, with or without 
subsequent treatment with TPA. As can be seen, 
neither antibody precipitated substantial amounts of 
[32P]phosphate-labeled material migrating in the 35-40 
kDa range. Less than 0.01 mol [32P]phosphate per mol 
of ai and less than 0.01 mol/mol of CY~ could be 
detected, regardless of whether cells had been treated 
with TPA or not. (The faintly labeled bands at 45 kDa 
in immunoprecipitates do not represent as, which clear- 
ly migrates faster.) 
It should be noted that the failure to detect [32P]phos- 
phate incorporation into subunits of G-proteins was not 
a result of interference by possible modifications with 
the antibody reaction (not shown). 
Next we addressed the catalytic moiety of the ade- 
nylyl cyclase system. Fig. 2 shows the autoradiograph 
Fig. 1. Immunoprecipitation of [32P]phosphate-labeled platelet pro- 
teins by antipeptide antisera 6712 (anti-c& and 6702 (anti-B). Mcm- 
branes (3 mg), from [3ZP]phosphate-labeIed platelets, treated with 
(+) or without (-) TPA were solubilized at 5 mg/ml in RIPA and 
heated to 100°C for 5 min. 120 ~1 antisera 6702 or 6712 were added 
and left for 2 h at 4°C. The mixture was added to 300 gl packed Pan- 
sorbin cells and the slurry agitated gently for 1 h at 4°C. After cen- 
trifugation (2000 x g) the pellet was washed 4 times with 1.5 ml each 
of ice-cold RIPA (2000 x g, 5 mitt). The washed pellet was treated 
with 250 al of Laemmli’s sample buffer for 5 min at 100°C and 200 
111 of the supernatant were applied to an 11% polyacrylamide gel. Pro- 
tein trapped by Pansorbin was estimated in parallel using [‘*P]ADP- 
ribosylated oli as tracer. The first two lanes represent RIPA- 
solubilized [““P]phosphorylated platelet membranes (100 pg). Dried 
gels were exposed to films for 14 h. 
of a 5-15070 gradient SDS-polyacrylamide gel of im- 
munoprecipitates obtained with the adenylyl cyclase 
specific antibody BBC-4, it may be seen that a 150 kDa 
peptide contained considerably more [32P]phosphate- 
label if it was derived from platelets previously treated 
with TPA. As a result a stoichiometry of 0.67-I. 1 mol 
[32P]phosphate per mol of catalytic subunit was obtain- 
ed for cells that had been treated with TPA. For the 
catalyst from untreated platelets a stoichiometry of 
0.13-0.2 was found. Phosphorylation of the catalyst 
concomitant with enhancement of adenylyl cyclase ac- 
tivity has also been. reported for the enzyme in frog 
erythrocyte membranes [38]. 
Absence of modification of ai via TPA was also in- 
dicated after functional reconstitution of pure GTP+- 
activated ai with platelet membranes (Fig. 3). Adenylyl 
cyclase from untreated platelets was considerably more 
inhibited by ai than that from treated platelets, ir- 
respective of whether the enzyme was activated via en- 
dogenous G, (PGEl/GTP) or via exogenous Gs (from 
101 
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TPA - 
Fig. 2. 
turkey erythrocytes). Inhibition of membrane-bound 
adenylyl cyclase by ai was first reported by Katada et al. 
[39] and recently also by Kobayashi et al. using G,- 
reconstituted S49 cyc - -membranes [40]. In contrast to 
the latter authors, we found that inhibition by ai was 
mainly of the non-competitive type (H.D. Schulzki, un- 
published), suggesting non-identical sites for ai and ols 
on the catalyst. The action of (pi has to be compared to 
that of the cxz-adrenergic agonist epinephrine and that 
of Gpp(NH)p which also affected adenylyl cyclase from 
TPA-treated and non-treated platelets differently. 
Likewise, the &y-moiety of G-proteins was inhibitory 
to platelet adenylyl cyclase, as has been shown 
previously by others [39]. But, when compared to ai, 
/3,y-subunits did not discriminate between the control 
and the TPA treated system. However, phosphoryla- 
tion of the P-moiety of platelet G-proteins seems to be 
unlikely, for another reason as well: isoelectric focus- 
sing did not reveal a TPA-induced shift in p1 compati- 
ble with such modification. Attenuation of enzymatic 
activity was not observed when ai was not activated by 
GTPyS or when ai was replaced by o10 (not shown). 
102 
PGEl IGTP-stimulated * Gs-stimulated 
0 5 IO 0 5 10 
mg - ’ x min- ’ (+ TPA). B. Inhibition of 
&-stimulated adenylyl cyclasc. Membranes (20 fig) from untreated 
(0,O) and TPA treated (A, A) platelets were assayed for adenylyl 
cyclase activity in the presence of 100 ng/ml GTP-&-activated Gr 
(turkey erythrocytes) and the indicated concentrations of GTP+- 
activated Oli (A.0) or &r-subunits (A ,e) respectively. 100% activity 
refers to 160 pmol x mg- ’ x min- ’ (-TPA) and 232 pmol x mg- ’ 
x min - ’ (+ TPA). Unstimulated adenylyl cyclasc activity (A and B) 
was 25 pmol x mg-’ x min-’ in membranes from untreated 
platelets and 38 pmol x mg x min-’ in membranes from TPA- 
treated platelets. Activation of G, (0.4 ~~g/ml) and ai (41 pg/ml) was 
achieved by incubation with 100 pM and 20 bM GTP$, respectively 
in 10 mM M&12, 0.5 mM Tween 60, 50 mM MOPS buffer, pH 7.4 
for 20 min at 30°C. Excessive GTPyS was removed by centrifugation 
through dehydrated Sephadex G-25 fine in 50 mM MOPS, pH 7.4, 
100 mM NaCI, 0.5 mM Tween 60,Z mg/ml bovine serum albumin. In 
order to overcome the effect of any transferred GTPyS, assays were 
conducted at high (50pM) GTP concentration which by itself did not 
cause a significant change in adenylyl cyclase activity. For com- 
parison, inhibition by IO IIM (-) epinephrine (Epi) or 75 FM 
Gpp(NH)p (G) is shown (see arrows). The effect of epinephrine was 
completely blocked by IO NM yohimbine. This experiment is represen- 
tative for 5 independently conducted experiments with different mem- 
brane preparations. 
The effects of reconstitution with ai and B,y-complex 
presented in Fig. 3 on a percentage basis, suggest that 
enhancement of enzymatic activity and attenuation of 
hormonal inhibition are separable events. Although a 
direct relationship cannot be excluded so far, this would 
also exclude ai and the P,y-complex as targets of TPA- 
action, because then the relative inhibition should be 
even greater when these were reconstituted with the 
TPA-treated system. Attenuation of hormonal inhibi- 
tion could be explained by modification of the 
az-adrenoceptor itself. Whilst this may be occurring as 
well, it can, of course, not explain the failure of GTP- 
analogs and purified ai to inhibit platelet adenylyl 
cyclase. Therefore modification of the catalyst itself, 
via phosphorylation, as reported here, must be taken 
Vo:ume 285, number i FEES LETTEl?S 
into consideration. This means then that the 
phosphorylated catalytic moiety must be less effective 
in interacting with ai. A definite answer to this question 
has to await reconstitution experiments employing pure 
catalyst in its phosphorylated and non-phosphorylated 
form. 
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